Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation

NCT00720356 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT00720356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00720356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Completed
Start date
July 7, 2009
Completion date
July 5, 2018
Enrollment
115 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors